MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.74
+0.43
+0.52%
After Hours: 82.74 0 0.00% 16:52 05/07 EDT
OPEN
82.49
PREV CLOSE
82.31
HIGH
84.26
LOW
82.12
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
110.37
52 WEEK LOW
75.52
MARKET CAP
18.20B
P/E (TTM)
38.09
1D
5D
1M
3M
1Y
5Y
Incyte Corp. stock rises Friday, still underperforms market
Shares of Incyte Corp. inched 0.52% higher to $82.74 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...
marketwatch.com · 2h ago
Tumor Necrosis Factor Receptor Superfamily Member 4 Market Segmentation and Forecasts 2021 to 2028 By Ameco Research
Comserve · 13h ago
Vitiligo Treatment Market Size, Share, Trends, Analysis and Forecast 2027
Market Insight Reports · 13h ago
Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028
Comserve · 14h ago
Fibroblast Growth Factor Receptor 2 Market Manufacturers Analysis and Forecast 2021-2028 By Ameco Research
Comserve · 15h ago
Bromodomain Containing Protein 2 Market : Global Industry Analysis and Opportunity Assessment 2028 By Ameco Research
pune, India, Fri, 07 May 2021 03:15:41 / Comserve Inc. / -- The global Bromodomain Containing Protein 2 market is segmented by company, region (country), by...
Comserve · 15h ago
Roberts Glore & Co Inc Buys iShares MSCI Emerging Markets ETF, International Flavors & ...
GuruFocus News · 16h ago
Incyte Corp. stock rises Thursday, outperforms market
marketwatch.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INCY. Analyze the recent business situations of Incyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INCY stock price target is 105.07 with a high estimate of 136.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 786
Institutional Holdings: 218.10M
% Owned: 99.19%
Shares Outstanding: 219.92M
TypeInstitutionsShares
Increased
181
8.71M
New
66
1.64M
Decreased
170
8.37M
Sold Out
55
820.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Herve Hoppenot
Chief Financial Officer/Executive Vice President
Christiana Stamoulis
Executive Vice President/Chief Scientific Officer
Dashyant Dhanak
Executive Vice President/General Counsel
Maria Pasquale
Executive Vice President/Director of Human Resources
Paula Swain
Executive Vice President
Barry Flannelly
Executive Vice President
Vijay Iyengar
Executive Vice President
Steven Stein
Executive Vice President
Wenqing Yao
Lead Director/Independent Director
Julian Baker
Independent Director
Jean-Jacques Bienaime
Independent Director
Paul Clancy
Independent Director
Wendy Dixon
Independent Director
Jacqualyn Fouse
Independent Director
Paul Friedman
Independent Director
Edmund Harrigan
Independent Director
Katherine High
No Data
About INCY
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.